MS4A1 and neoplasm: A prompt treatment with the bispecific CD20/CD3 antibody glofitamab was initiated together with a single dose of preceding obinutuzumab to mitigate the risk of tumor lysis and CRS and ICANS, as prescribed by the manufacturer.